According to a press release from the business, Viz.ai has secured a US$100 million fundraising round at a US$1.2 billion value. The hospitals employing the Viz platform now number over 1,000, and millions of patients have been served. Tiger Global and Insight Partners lead the Series D financing. Several of the company’s early backers, such as Scale Ventures, Kleiner Perkins, Threshold, GV (previously Google Ventures), Sozo Ventures, CRV, and Susa, also participated in the round.
According to the press release, the additional money will be utilized to enhance the Viz platform to detect and prioritize more diseases as well as expand Viz.ai’s customer base globally.
The business keeps broadening its influence and innovating in new illness conditions. Viz.ai asserts that one patient receives assistance in their care every 32 seconds through their extensive network of hospitals and health system clients.
Viz.ai has introduced artificial intelligence (AI)-driven treatments for aortic disease, pulmonary embolism, and cerebral aneurysms, and is currently 510(k)-pending with the US Food and Drug Administration (FDA) for subdural hemorrhage. Additionally, the business received its first five CE marks in 2021, which were followed by contracts with several prestigious institutions.
According to Chris Mansi, co-founder, and CEO of Viz.ai, “Viz.ai is committed to helping patients gain better, faster, and more equal access to life-saving medications.” To fully integrate into the clinical workflow, we will keep investing extensively in cutting-edge technology and services. This will enable us to automate disease identification, boost diagnostic rates, and improve workflows throughout the whole hub and spoke health care system. Most clients receive the appropriate care, improving patient outcomes and the health system’s cost efficiency.
The investment announcement comes in the wake of the debut of Viz.ai’s ground-breaking AI-driven life science platform, a first-of-its-kind innovation that transforms how pharmaceutical and medical device businesses conduct clinical trials and sells their products. Several of the biggest life science businesses in the world have relationships with Viz.ai. These businesses are closely watching as they increasingly turn to digital health to support and strengthen their conventional efforts. According to Chris Kellner, MD, a cerebrovascular neurosurgeon with the Mount Sinai Health System in New York, “The Viz.ai platform has been the single most impactful advancement I’ve seen as a physician, permitting the entire care team to mobilize instantaneously and deliver time-sensitive treatment faster.” Viz Recruit also enables us to systematically screen patients for clinical trial enrollment, ensuring that we can provide cutting-edge research and therapies to a greater number of eligible patients.